{"id":"zsp1273","safety":{"commonSideEffects":[{"rate":"5%","effect":"Nausea"},{"rate":"4%","effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"featherless-qwen","explanation":"By inhibiting the RNA-dependent RNA polymerase, ZSP1273 prevents the influenza virus from replicating its genetic material, thereby reducing viral load and mitigating the severity of the infection.","oneSentence":"ZSP1273 is an influenza virus RNA-dependent RNA polymerase inhibitor that blocks viral replication.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:41:37.957Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of acute uncomplicated influenza A and B in adults and adolescents aged 12 years and older"}]},"trialDetails":[{"nctId":"NCT07229820","phase":"PHASE3","title":"Efficacy and Safety of ZSP1273 in Children 12-17 Years Old With Influenza A","status":"ACTIVE_NOT_RECRUITING","sponsor":"Guangdong Raynovent Biotech Co., Ltd","startDate":"2025-11-08","conditions":"Influenza A","enrollment":157},{"nctId":"NCT07229807","phase":"PHASE3","title":"Efficacy and Safety of ZSP1273 in Children 2-11 Years Old With Influenza A","status":"ACTIVE_NOT_RECRUITING","sponsor":"Guangdong Raynovent Biotech Co., Ltd","startDate":"2025-11-22","conditions":"Influenza a","enrollment":119},{"nctId":"NCT06656026","phase":"PHASE2","title":"Pharmacokinetics，Safety and Efficacy of ZSP1273 in Children 2-17 Years Old With Influenza A","status":"COMPLETED","sponsor":"Guangdong Raynovent Biotech Co., Ltd","startDate":"2024-11-30","conditions":"Influenza a","enrollment":72},{"nctId":"NCT05873426","phase":"PHASE1","title":"Mass Balance Study of [14C]ZSP1273 in Healthy Adult Male Subjects in China","status":"COMPLETED","sponsor":"Guangdong Raynovent Biotech Co., Ltd","startDate":"2023-03-25","conditions":"Pharmacokinetics","enrollment":6},{"nctId":"NCT06248567","phase":"PHASE1","title":"Pharmacokinetics of ZSP1273 in Participants With Severe Kidney Disease","status":"COMPLETED","sponsor":"Guangdong Raynovent Biotech Co., Ltd","startDate":"2024-01-15","conditions":"Kidney Impairment","enrollment":16},{"nctId":"NCT06164431","phase":"PHASE1","title":"Bioavailability Study in Healthy Participants, 200mg Tablets ZSP1273 Versus 200mg Granules ZSP1273","status":"COMPLETED","sponsor":"Guangdong Raynovent Biotech Co., Ltd","startDate":"2023-11-23","conditions":"Bioequivalence","enrollment":32},{"nctId":"NCT05954624","phase":"PHASE1","title":"Drug-durg Interaction of ZSP1273 With Digoxin, Rosuvastatin,Itraconazole and Probenecid","status":"COMPLETED","sponsor":"Guangdong Raynovent Biotech Co., Ltd","startDate":"2023-07-10","conditions":"Drug Drug Interaction","enrollment":49},{"nctId":"NCT05942365","phase":"PHASE1","title":"A Drug Interaction Study Assess the Effects of ZSP1273 Tablets on the Pharmacokinetics of Warfarin and Midazolam","status":"COMPLETED","sponsor":"Guangdong Raynovent Biotech Co., Ltd","startDate":"2023-06-25","conditions":"Drug Drug Interaction, Warfarin, Midazolam","enrollment":28},{"nctId":"NCT06157450","phase":"PHASE1","title":"Pharmacokinetics of ZSP1273 in Elder Participants","status":"COMPLETED","sponsor":"Guangdong Raynovent Biotech Co., Ltd","startDate":"2023-10-11","conditions":"Elder","enrollment":32},{"nctId":"NCT05856513","phase":"PHASE1","title":"Pharmacokinetics of ZSP1273 in Participants With Hepatic Impairment","status":"COMPLETED","sponsor":"Guangdong Raynovent Biotech Co., Ltd","startDate":"2023-06-15","conditions":"Hepatic Impairment, Pharmacokinetics","enrollment":24},{"nctId":"NCT04683406","phase":"PHASE3","title":"A Study of ZSP1273 Tablets in Patients With Acute Uncomplicated Influenza A","status":"COMPLETED","sponsor":"Guangdong Raynovent Biotech Co., Ltd","startDate":"2020-12-28","conditions":"Influenza A","enrollment":750},{"nctId":"NCT05108051","phase":"PHASE1","title":"Study to Investigate the Potential Drug-Drug Interaction Between ZSP1273 and Oseltamivir","status":"COMPLETED","sponsor":"Guangdong Raynovent Biotech Co., Ltd","startDate":"2020-11-19","conditions":"Drug-drug Interaction","enrollment":36},{"nctId":"NCT04024137","phase":"PHASE2","title":"Study of ZSP1273 in Patients With Acute Uncomplicated Influenza A","status":"COMPLETED","sponsor":"Guangdong Raynovent Biotech Co., Ltd","startDate":"2019-12-07","conditions":"Influenza A","enrollment":172},{"nctId":"NCT03679143","phase":"PHASE1","title":"The Safety, Tolerability and Pharmacokinetic Study of ZSP1273 in Healthy Volunteers.","status":"COMPLETED","sponsor":"Guangdong Zhongsheng Pharmaceutical Co., Ltd.","startDate":"2018-09-20","conditions":"Influenza","enrollment":103}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":6,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"ZSP1273","genericName":"ZSP1273","companyName":"Guangdong Raynovent Biotech Co., Ltd","companyId":"guangdong-raynovent-biotech-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ZSP1273 is an influenza virus RNA-dependent RNA polymerase inhibitor that blocks viral replication. Used for Treatment of acute uncomplicated influenza A and B in adults and adolescents aged 12 years and older.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}